Dxcover

Every 1.6 seconds, someone is diagnosed with cancer. This month, Dxcover will be attending the ESMO - European Society for Medical Oncology Congress 2025 in #Berlin, October 17-21, joining oncology experts, researchers, and innovators shaping the future of cancer care.    As a leading platform combining liquid biopsy & #AI for early cancer detection, we look forward to sharing our mission to improve survival through earlier diagnosis and intervention. Arrange a meeting with us on-site via our LinkedIn page, or visit our website to learn more: https://www.dxcover.com/ #ESMO2025 #Oncology #CancerDetection #MedTech

We're proud to have had John D., Chief Financial Officer, representing team Dxcover at Scotland’s Global Investment Summit in Edinburgh, 6–7 October 2025. It's an honour to play a part in Scotland's growing role as a hub for global innovation, particularly in the MedTech sector. We are determined to continue our mission to make early cancer detection accessible through innovative liquid biopsy and AI technology, bringing our platform to global communities including the UK, US, and Europe. Connect with us to learn more about our vision, or visit our website to discover our PANAROMIC platform for earlier detection of cancer: https://www.dxcover.com/

We're looking forward to connecting with leading investors and peers today at the Future of Healthcare Investment Forum at London Stock Exchange, to discuss innovation across the health industry and Dxcover's journey to bring accessible, early cancer detection to patients. As our platform accelerates toward CE-IVDR approval across the UK & Europe, as well as a CLIA LDT launch in the US, we're excited to pave the way for scalable and accessible early detection. Connect with us on LinkedIn to learn more, or visit https://www.dxcover.com/

We’re delighted to be in Paris today, pitching in the Medtech & Digital session at the EIC - European Innovation Council Healthcare Investor Day, powered by EuroQuity - Bpifrance.    Come and meet the Dxcover team to learn how our #PANAROMIC platform combines liquid biopsy and artificial intelligence to enable the early detection of multiple cancers and other diseases, improving survival and quality of life through earlier intervention.   Following UKCA and upcoming CE-IVDR approvals, we’re now scaling our platform across Europe and beyond to make earlier diagnosis accessible to more patients.   Learn more: https://www.dxcover.com/   #MedTech #AIinHealthcare #LiquidBiopsy #EarlyDetection #CancerDiagnostics #CEIVDR #UKCA #EICAccelerator #HealthInnovation

There's still time to arrange a meeting with us on-site at the EIC - European Innovation Council's Healthcare Investor Day powered by EuroQuity - Bpifrance in #Paris on Monday, 6 October, where we will be pitching on the Medtech & Digital session, alongside industry experts at the centre of European healthcare. Reach out via the Dxcover LinkedIn page to arrange a meeting with us on-site, or to learn more about Dxcover, visit: https://www.dxcover.com/ #EUeic

There's still time to arrange a meeting with us on-site at the EIC - European Innovation Council's Healthcare Investor Day powered by EuroQuity - Bpifrance in #Paris on Monday, 6 October, where we will be pitching on the Medtech & Digital session, alongside industry experts at the centre of European healthcare. Reach out via the Dxcover LinkedIn page to arrange a meeting with us on-site, or to learn more about Dxcover, visit: https://www.dxcover.com/ #EUeic

Globally, September 30 is recognised as Rare Cancer Day. Spearheaded by National Organization for Rare Disorders, #RareCancerDay highlights the challenges faced by patients with rare cancers and advocates for early detection, research, and better access to treatments.    Rare cancer diagnoses affect more people than you may think. The rare cancer Glioblastoma, for example, is the most common and aggressive primary brain tumour in adults, accounting for 48% of all primary malignant tumours (Glioblastoma Research Organization, 2018-2024).    We are reminded every day of our goal to bring early cancer detection to as many patient communities as possible. Dxcover's spectroscopic liquid biopsy is a simple blood test combining next generation technology that can rapidly fast track patients suspected to have cancers, including brain tumours, for further treatment.   Our #PANAROMIC platform for earlier detection of cancer is a testament to our belief that the future of cancer detection and treatment can and must change to provide better outcomes for every patient. Learn more about the science behind our PANAROMIC platform and the future of cancer detection: https://lnkd.in/exZeH2Nf

It's an exciting time for Dxcover to join 2025 Invest2Scale in Scotland, an event dedicated to bridging gaps between Scotland and the global investor community. As our novel platform moves toward CE-IVDR approval across the UK & Europe, as well as a CLIA LDT launch in the US, we're excited to share our efforts to bring accessible early detection of cancer to the global market. Reach out on LinkedIn to arrange a meeting with us on-site, or learn more about our journey transforming cancer diagnostics, here: https://www.dxcover.com/

The nominees have been announced for the Insider Scotland Dealmakers Awards 2025. Congratulations to all the nominees, particularly Scottish Enterprise's investee companies SOLASTA® Bio (Deal of the Year (£10m- £50m) and Dxcover (Deal of the Year (sub £10m) - good luck on 12 November! https://lnkd.in/eErMtmQP #investment #scaling

Dxcover was honoured to join The Scottish Government First Minister, John Swinney, and Minister for Business and Employment, Richard Lochhead, supported by Director General, Economy, Gregor Irwin, Deputy Director, Innovation and Industrial Transformation, Suresh Kumar, Chief Entrepreneur, Ana Stewart, and Chief Business Advisor to FM, Ellis Watson, during Scotland's First National Innovation Week on Thursday, September 25. We’re proud of our Scottish origins with our company foundations at the University of Strathclyde, launching our innovative "Drop, Dry, Detect" technology which targets early-stage cancers, including brain, colorectal, and lung cancer. With clinical trials underway, we continue to work toward improving survival rates through accessible early diagnosis of cancer. As a company dedicated to driving innovation in the health sector, we're grateful to share a platform with industry peers and academia representing Scotland's thriving tech ecosystem. Learn more about Dxcover, here: https://www.dxcover.com/